Member Info for Hurst10

The 5th test cancellation, would never happened if a rapid LFT antigen tests had taken place, there and then.
Embarrassing !!

As pointed out earlier, they will have to discuss the role of Rapid antigen LFT”
Read the statement in full.
Interesting ahead

Avacta could receive emergency approval from the FDA:
A new six-point plan, announced by President Joe Biden on Thursday to fight the pandemic requiring COVID-19 vaccinations or regular testing for nearly two-thirds of U.S. employees could overwhelm the manufacturers of COVID-19 tests, industry experts argue.
While lab-based capacity is strong, the rapid point-of-care test supplies are still ramping up, Reuters reported quoting the Advanced Medical Technology Association, a trade group of test manufacturers.
The U.S. test makers can only produce about 50 million COVID -19 rapid antigen tests per month, Evercore ISI Vijay Kumar points out. That is sufficient for only about 12 million people to undergo weekly testing.
Meanwhile, according to data from the Centers for Disease Control and Prevention (CDC), about 25% of 255 million U.S. adults have yet to receive a COVID-19 shot.
US covid test makers moving higher!

The Emergency Use Authorization (EUA) authority allows FDA to help strengthen the nation’s public health protections against chemical, biological, radiological, and nuclear (CBRN) threats including infectious diseases, by facilitating the availability and use of medical countermeasures (MCMs) needed during public health emergencies.

US index funds buying and when they do, they have a following, watch the price closing 140+

Morgan Stanley conference starting on Monday.
Precision oncology will be a theme and so will Radiotherapy.
Avacta?s friend and JV partner Moderna will make a lot of noise apart from their vaccine efforts !!
New board members
M&A will be discussed as well.

Morgan Stanley conference starting on Monday.
Precision oncology will be a theme and so will Radiotherapy.
Avacta?s friend and JV partner Moderna will make a lot of noise apart from their vaccine efforts !!
M&A will be discussed as well.

Recent weeks have underlined that we will not hesitate to take action against any PCR test provider we suspect is breaking the law and exploiting their customers

Andrea Coscelli, CMA

Statement just out

Coming into US hours, watch Peel Hunt go “ Best bid and 10 p spread ie. worst offer and the buying starts

OTC approval here we come
Amazon next

Headlines in Australia this morning:

“Home testing key to living with COVID, but Australia a two-tier country: Doherty Institute”

https://www.ddw-online.com/building-a-pipeline-of-clinically-differentiated-cancer-therapies-13092-202109/

What one has to remember is once EU OTC incl Australia, SA etc is being launched I suspect Medusa is telling us is before end of next week, the current monthly manufacturing est of 15 mill , can as per the ceo be doubled, Asian manufacturing, then our numbers look very different.

Amazing couple of weeks ahead of us!!!!
144-50 AM

ADC Therapeutics to present at Morgan Stanley Healthcare conference, more on PBD Warheads.

Several blocks of 35/ and 55/ on the buying going through

M&A across the testing sector PCR, Lateral flow etc. shows the market, that the majors understand testing is here to stay!

Following Maersk’s recent tie up up with QFI, to develop marine versionMSAR emulsion fuel, Maersk are clearly out expanding in the whole area and investing as well.
The lastest deal :
Three weeks after the announcement of an e-methanol sourcing agreement in Europe, A.P. Moller – Maersk invests in California-based WasteFuel, a start-up focused on turning waste into sustainable aviation fuel, green bio-methanol, and renewable natural gas. This investment is made through Maersk Growth, the corporate venture arm of A.P. Moller – Maersk.
Maersk Ventures to invest in QFI next!

I assume we have this news before Canada, so second wave of buying at midday.

NorthStar Medical Radioisotopes and POINT Biopharma Announce Supply Agreement for Therapeutic Medical Radioisotope Actinium-225
BELOIT, Wis. and INDIANAPOLIS, Ind., September 8, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today announced the signing of a supply agreement for the therapeutic medical radioisotope actinium-225 (Ac-225).
Back in January :
“
Avacta Group plc, the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that it has entered into a licence agreement with POINT Biopharma Inc., to provide access to Avacta’s pre|CISION technology for the development of tumour-activated radiopharmaceuticals.
The radiopharmaceutical market is expected to grow to $15 billion by 20251 and there is a substantial opportunity to grow much faster if safety and tolerability of these effective treatments can be improved. POINT Biopharma is a clinical-stage pharmaceutical company focused on developing radioligands2 as precision medicines for the treatment of cancer.

The government has no plans for a “firebreak” lockdown in October but has contingencies that could be introduced as a “last resort” to protect the NHS, Downing Street said.
“The prime minister’s official spokesman said reports that ministers were considering emergency lockdown plans over the half-term school holidays next month were “not true”.”
The demand for rapid accurate rapid antigen tests will be in high demand.

One would expect OTC approval any day and off course, that will include Europe etc.
+ we have results very shortly, plenty of fireworks to come.
By the end of the month we should have the price in 245-50 level, with only a fraction of future OTC sales in the SOP.
With proper analysis of est. UK and Overseas professional and OTC sales and future updates from the Phase 1 trials, you can easily arrive at a SOP north of 500p, prior to a Nasdaq listing with future revised valuation.
PS did I mention Korean JV’s and the US Radio therapy JV, well you will have a whole new Avacta.
Best thing out of Cambridge since Arm Holdings!!
Did only thing that would spoil the party is one of the majors knocking on the door and snap it up.